Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection
Brief Summary: The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: Velpatasvir 5 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 100 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1b); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 4); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir up to 400 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Velpatasvir; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2)
C: Arm Label: PegIFN-2b + RBV; Type: PLACEBO_COMPARATOR; Interventions: Drug: PegIFN-2b, Drug: RBV, Drug: Placebo to Boceprevir | Arm Label: PegIFN-2b + RBV + Boceprevir; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN-2b, Drug: RBV, Drug: Boceprevir | Intervention Type: DRUG; Name: PegIFN-2b; Assigned to Arm(s): PegIFN-2b + RBV, PegIFN-2b + RBV + Boceprevir | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PegIFN-2b + RBV, PegIFN-2b + RBV + Boceprevir | Intervention Type: DRUG; Name: Placebo to Boceprevir; Assigned to Arm(s): PegIFN-2b + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): PegIFN-2b + RBV + Boceprevir
D: Arm Label: Treatment Arm A; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: VX-222 | Arm Label: Treatment Arm B; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: VX-222 | Arm Label: Treatment Arm C; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: VX-222, Drug: ribavirin, Biological: peginterferon-alfa-2a | Arm Label: Treatment Arm D; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon-alfa-2a, Drug: VX-222 | Arm Label: Treatment Arm E; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Drug: VX-222 | Arm Label: Treatment Arm F; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Drug: VX-222 | Intervention Type: DRUG; Name: telaprevir; Assigned to Arm(s): Treatment Arm A, Treatment Arm B, Treatment Arm C, Treatment Arm D, Treatment Arm E, Treatment Arm F | Intervention Type: DRUG; Name: VX-222; Assigned to Arm(s): Treatment Arm A, Treatment Arm C | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Treatment Arm C, Treatment Arm D, Treatment Arm E, Treatment Arm F | Intervention Type: BIOLOGICAL; Name: peginterferon-alfa-2a; Assigned to Arm(s): Treatment Arm C, Treatment Arm D | Intervention Type: DRUG; Name: VX-222; Assigned to Arm(s): Treatment Arm B, Treatment Arm D, Treatment Arm E, Treatment Arm F

Answer: B